lixivaptan
Small moleculeexperimental
Lixivaptan (VPA-985) is an orally-active, non-peptide, selective vasopressin V2 receptor antagonist being developed as an investigational drug by Palladio Biosciences, Inc. (Palladio), a subsidiary of Centessa Pharmaceuticals plc. As of December 2021, lixivaptan is in phase III clinical development for the treatment of autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to lixivaptan for the treatment of ADPKD. — Wikipedia
Clinical trial activity
11 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
10
Phase 3
7
Phase 4
0
Earliest trial started Jan 1, 2007 (NCT00578695)
Timeline
Indications
Mechanism of action
- Vasopressin V2 receptorANTAGONIST
AVPR2 antagonist
FDA has denied approval.
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc32)c(Cl)c1- Mol. weight
- 473.94 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLixivaptan ↗
- ChEMBLCHEMBL49429 ↗
Also known as
- 5-fluoro-2-methyl-n-(4-(5h-pyrrolo(2,1-c)-(1,4)benzodiazepin-10-(11h)-ylcarbonyl)-3-chlorophenyl)benzamide
- crtx-080
- crtx-080
- lixivaptan
- lixivaptan
- lixivaptan
- lixivaptan
- n-4-(3-chloro-4-(5h-pyrrolo(2,1-c)(1,4)benzodiazepin-10(11h)-ylcarbonyl)phenyl)-5-fluoro-2-methylbenzamide
- vpa 985
- vpa-985
- vpa-985
- vpa-985
- way vpa-985
- way-vpa-985
- way-vpa-985
- way-vpa-985
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05208866 | Phase 3 | Feb 10, 2022 | Centessa, Palladio Biosciences |
| NCT04064346 | Phase 3 | Mar 31, 2020 | Palladio Biosciences |
| NCT04152837 | Phase 3 | Feb 29, 2020 | Palladio Biosciences |
| NCT03717181 | Phase 2 | Jan 1, 2019 | Palladio Biosciences |
| NCT03487913 | Phase 2 | Sep 14, 2018 | Palladio Biosciences |
| NCT01055912 | Phase 2 | Jan 1, 2010 | CardioKine Inc. |
| NCT00876876 | Phase 3 | Jul 1, 2009 | Biogen, CardioKine Inc. |
| NCT00876798 | Phase 3 | Jun 1, 2009 | Biogen, CardioKine Inc. |
| NCT00675701 | Phase 1 | May 1, 2008 | Biogen, CardioKine Inc. |
| NCT00660959 | Phase 3 | Apr 1, 2008 | Biogen, CardioKine Inc. |
| NCT00578695 | Phase 3 | Jan 1, 2007 | Biogen, CardioKine Inc. |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CardioKine Inc. | For profit | 6 | 6 | 3 | 2007 |
| Biogen | For profit | 5 | 0 | 2 | 2007 |
| Palladio Biosciences | For profit | 5 | 5 | 2 | 2018 |
| Centessa | For profit | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1